Endoscopy 2012; 44(01): 74-94
DOI: 10.1055/s-0031-1291491
Guideline
© Georg Thieme Verlag KG Stuttgart · New York

Management of precancerous conditions and lesions in the stomach (MAPS): guideline from the European Society of Gastrointestinal Endoscopy (ESGE), European Helicobacter Study Group (EHSG), European Society of Pathology (ESP), and the Sociedade Portuguesa de Endoscopia Digestiva (SPED)

M. Dinis-Ribeiro*
 1  Department of Gastroenterology, Portuguese Oncology Institute of Porto, Portugal
 5  Centre for Research in Health Technologies and Information Systems (CINTESIS), Medical Faculty, Porto, Portugal
,
M. Areia
 2  Department of Gastroenterology, Portuguese Oncology Institute of Coimbra, Portugal
 5  Centre for Research in Health Technologies and Information Systems (CINTESIS), Medical Faculty, Porto, Portugal
,
A. C. de Vries
 3  Department of Gastroenterology and Hepatology, Erasmus MC, Rotterdam, The Netherlands
,
R. Marcos-Pinto
 4  Department of Gastroenterology, Centro Hospitalar do Porto, Portugal
 6  Institute of Biomedical Sciences, University of Porto (ICBAS/UP), Porto, Portugal
,
M. Monteiro-Soares
 5  Centre for Research in Health Technologies and Information Systems (CINTESIS), Medical Faculty, Porto, Portugal
,
A. O’Connor
 7  AMNCH/TCD, Adelaide and Meath Hospital/Trinity College, Gastroenterology Department, Dublin, Ireland
,
C. Pereira
 8  Molecular Oncology Research Group, Portuguese Oncology Institute of Porto, Portugal
,
P. Pimentel-Nunes
 1  Department of Gastroenterology, Portuguese Oncology Institute of Porto, Portugal
,
R. Correia
 5  Centre for Research in Health Technologies and Information Systems (CINTESIS), Medical Faculty, Porto, Portugal
,
A. Ensari
 9  Department of Pathology, Ankara University Medical School, Ankara, Turkey
,
J. M. Dumonceau
10  Département de Gastroénterologie et d’Hépatopancréatologie, H.U.G. Hôpital Cantonal, Geneve, Switzerland
,
J. C. Machado
11  Institute of Molecular Pathology and Immunology of the University of Porto (IPATIMUP), Porto, Portugal
,
G. Macedo§
12  Department of Gastroenterology, Centro Hospitalar S. João/Medical Faculty, Porto, Portugal
,
P. Malfertheiner
13  Klinik der Gasroenterologie, Hepatologie und Infektologie, Otto von Guericke Universität Magdeburg, Magdeburg, Germany
,
T. Matysiak-Budnik
14  Service d’Hépato-Gastroentérologie, Hôtel Dieu, CHU de Nantes, Nantes, France
,
F. Megraud
15  Inserm U853 & Université Bordeaux, Laboratoire de Bacteriologie, Bordeaux, France
,
K. Miki
16  Japan Research Foundation of Prediction, Diagnosis and Therapy for Gastric Cancer (JRF PDT GC), Tokyo, Japan
,
C. O’Morain
 7  AMNCH/TCD, Adelaide and Meath Hospital/Trinity College, Gastroenterology Department, Dublin, Ireland
,
R. M. Peek
17  Division of Gastroenterology, Vanderbilt University School of Medicine, Nashville, USA
,
T. Ponchon
18  Hôpital Edouard Herriot, Department of Digestive Diseases, Lyon, France
,
A. Ristimaki
19  Department of Pathology, HUSLAB and Haartman Institute, Helsinki University Central Hospital and University of Helsinki, Helsinki, Finland.
20  Genome-Scale Biology, Research Program Unit, University of Helsinki, Helsinki, Finland
,
B. Rembacken
21  Centre for Digestive Diseases, The General Infirmary at Leeds, Leeds, United Kingdom
,
F. Carneiro§
11  Institute of Molecular Pathology and Immunology of the University of Porto (IPATIMUP), Porto, Portugal
22  Department of Pathology, Medical Faculty/Centro Hospitalar S. João, Porto, Portugal
,
E. J. Kuipers**
 3  Department of Gastroenterology and Hepatology, Erasmus MC, Rotterdam, The Netherlands
› Institutsangaben
Weitere Informationen

Publikationsverlauf

Submitted: 04. August 2011

Accepted after revision: 12. Oktober 2011

Publikationsdatum:
23.Dezember 2011 (online)

Atrophic gastritis, intestinal metaplasia, and epithelial dysplasia of the stomach are common and are associated with an increased risk for gastric cancer. In the absence of guidelines, there is wide disparity in the management of patients with these premalignant conditions. The European Society of Gastrointestinal Endoscopy (ESGE), the European Helicobacter Study Group (EHSG), the European Society of Pathology (ESP) and the Sociedade Portuguesa de Endoscopia Digestiva (SPED) have therefore combined efforts to develop evidence-based guidelines on the management of patients with precancerous conditions and lesions of the stomach (termed MAPS). A multidisciplinary group of 63 experts from 24 countries developed these recommendations by means of repeat online voting and a meeting in June 2011 in Porto, Portugal. The recommendations emphasize the increased cancer risk in patients with gastric atrophy and metaplasia, and the need for adequate staging in the case of high grade dysplasia, and they focus on treatment and surveillance indications and methods.

* Chairman, ESGE Educational Committee, and Chairman, SPED Research Committee


Chairperson, ESP Digestive Pathology Working Group


Chairman, ESGE Guidelines Committee


§ President, Portuguese Society of Digestive Endoscopy


ESP Digestive Pathology Working Group


** on behalf of MAPS Participants. Including: Cathomas G (Switzerland), Fedorov ED (Russia), Figueiredo P (Portugal), Goldis A (Romania), Leja M (Latvia), Moehler M (Germany), Plesea E (Romania), Bergman J (The Netherlands), Hamoudi W (Jordan), Almeida R, Annibale B, Lobo LA, Balaban YH, Boeriu A, Burette A, Mallet AC, David L, Delchier J-C, Dobru ED, Fernandes C, Kahaleh M, Kashin S, Lomba-Viana R, Lunet N, Marakhouski K, Moreira-Dias L, Ferreira CF, Pais TP, Rollán A, Sadio A, Santos C, Chu K-M, D'Ambra G, Ellul P, van Grieken N, Lamarque D, Najeeb AA

**